Claims for Patent: 9,562,223

Summary for Patent: 9,562,223

Title:	Methods for reducing intraocular pressure by administering a soluble hyaluronidase glycoprotein (sHASEGP)
Abstract:	Provided are methods for reducing intraocular pressure in the eye of a subject by administering neutral active soluble active hyaluronidase glycoproteins (sHASEGPs) and modified forms thereof to the eye. The sHASEGPs are soluble forms of human PH20 hyaluronidase. Also provided are the sHASEGPs, methods of manufacture, and uses thereof. Minimally active polypeptide domains of the soluble, neutral active sHASEGP domains are described. The sHASEGPs include asparagine-linked sugar moieties required for a functional neutral active hyaluronidase domain.
Inventor(s):	Bookbinder; Louis (San Diego, CA), Kundu; Anirban (San Diego, CA), Frost; Gregory I. (Palm Beach, FL)
Assignee:	Halozyme, Inc. (San Diego, CA)
Application Number:	13/999,454
Patent Claims:	1. A method for reducing intraocular pressure in the eye of a subject, comprising administering a composition comprising a hyaluronidase polypeptide to the eye, wherein: the hyaluronidase polypeptide contains at least one sugar moiety that is covalently attached to an asparagine residue of the hyaluronidase polypeptide; the hyaluronidase polypeptide is catalytically active; the hyaluronidase polypeptide is secreted; and the hyaluronidase polypeptide consists of a sequence of amino acids that has at least 98% amino acid sequence identity with the sequence of amino acids set forth as amino acid residues 36-483 of SEQ ID NO:1. 2. The method of claim 1, wherein the hyaluronidase polypeptide has at least 99% amino acid sequence identity with the sequence of amino acids set forth as amino acid residues 36-483 of SEQ ID NO:1. 3. A method for reducing intraocular pressure in the eye of a subject, comprising administering a composition comprising a hyaluronidase polypeptide to the eye, wherein: the hyaluronidase polypeptide contains at least one sugar moiety that is covalently attached to an asparagine residue of the hyaluronidase polypeptide; the hyaluronidase polypeptide is catalytically active; the hyaluronidase polypeptide is secreted; and the hyaluronidase polypeptide either: (i) consists of the sequence of amino acids set forth as amino acids 36-477, 36-478, 36-479, 36-480, 36-481, 36-482 or 36-483 of SEQ ID NO:1; or (ii) has at least 95% sequence identity with the sequence of amino acids set forth as amino acids 36-477, 36-478, 36-479, 36-480, 36-481, 36-482 or 36-483 of SEQ ID NO:1, wherein the amino acid sequence of the hyaluronidase polypeptide differs from the sequence of amino acids set forth as amino acids 36-477, 36-478, 36-479, 36-480, 36-481, 36-482 or 36-483 of SEQ ID NO: 1 only by amino acid substitutions. 4. The method of claim 1, wherein the hyaluronidase polypeptide consists of residues 36-485 of SEQ ID NO:1. 5. The method of claim 1, wherein the hyaluronidase polypeptide is secreted when produced in CHO cells. 6. The method of claim 1, wherein the C-terminal residue of the hyaluronidase polypeptide in the composition is at a position corresponding to position 477, 478, 479, 480, 481, 482 or 483 of SEQ ID NO:1. 7. The method of claim 1, wherein the sequence of amino acid residues of the hyaluronidase polypeptide in the composition consists of residues 36-477, 36-478, 36-479, 36-480, 36-481, 36-482 or 36-483 of SEQ ID NO:1. 8. The method of claim 1, wherein the hyaluronidase polypeptide is chemically linked to a polymer. 9. The method of claim 3, wherein the hyaluronidase polypeptide is chemically linked to a polymer. 10. The method of claim 8, wherein the polymer is a polyethylene glycol (PEG) or a dextran. 11. The method of claim 10, wherein the polymer is a PEG. 12. The method of claim 9, wherein the polymer is a polyethylene glycol (PEG) or a dextran. 13. The method of claim 1, wherein the subject has glaucoma or has elevated intraocular pressure associated with cataracts or treatment of cataracts. 14. The method of claim 3, wherein the subject has glaucoma or has elevated intraocular pressure associated with cataracts or treatment of cataracts. 15. The method of claim 13, wherein the subject has been treated with viscoelastic substances. 16. The method of claim 13, wherein the subject has been treated with hyaluronic acid. 17. The method of claim 13, wherein the subject has open angle glaucoma. 18. The method of claim 1, wherein the subject has vitreous aggregates, vitreous hemorrhage, macular degeneration or diabetic retinopathy. 19. The method of claim 1, wherein the composition comprising the hyaluronidase polypeptide is co-administered with other enzymes that promote reshaping of the cornea by corrective contact lenses. 20. The method of claim 1, wherein the composition comprising the hyaluronidase polypeptide is administered intraocularly. 21. The method of claim 3, wherein the subject has vitreous aggregates, vitreous hemorrhage, macular degeneration or diabetic retinopathy. 22. The method of claim 3, wherein the composition comprising the hyaluronidase polypeptide is co-administered with other enzymes that promote reshaping of the cornea by corrective contact lenses. 23. The method of claim 3, wherein the composition comprising the hyaluronidase polypeptide is administered intraocularly. 24. The method of claim 3, wherein the hyaluronidase polypeptide consists of the sequence of amino acids set forth as amino acids 36-477, 36-478, 36-479, 36-480, 36-481, 36-482 or 36-483 of SEQ ID NO:1.

Details for Patent 9,562,223

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Bausch & Lomb Incorporated	VITRASE	hyaluronidase	Injection	021640	May 05, 2004		2023-03-05
Bausch & Lomb Incorporated	VITRASE	hyaluronidase	Injection	021640	December 02, 2004		2023-03-05
Amphastar Pharmaceuticals, Inc.	AMPHADASE	hyaluronidase	Injection	021665	October 26, 2004		2023-03-05